AKAlan D. Kitchen

Alan D. Kitchen

*This is an algorithmically generated author record based on publicly available information.

Alan D. Kitchen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Current information on the infectious risks of allogeneic blood transfusion

    by Alan D. Kitchen, John A. J. Barbara

    SUMMARY: The safety of allogeneic blood and blood products in relation to infection risk is paramount, even though absolute safety is an ideal that clearly cannot be attained. In countries with developed healthcare systems and with effective and well‐managed national transfusion services, any residual infection risk is generally much lower than the risk of non‐infectious adverse events. The number of infectious agents known to be transmitted by transfusion is not insignificant, but at the same time only a proportion of these present a significant universal threat. It is therefore important to understand and attempt to quantify the residual infectious risks associated with transfusion. These risks generally fall into two categories: the risk of infection because of the failure to identify infection in a donation from a recently infected donor and the risk of infection from a ‘new’ infectious agent or from one that donations are not routinely screened for. Both of these scenarios are ‘real’ in the sense that these are the threats faced every day by transfusion services. The mitigation of such threats is by ensuring that there are effective donor screening and deferral procedures in place, that the screening performed is carried out to the highest possible standards in terms of sensitivity and reliability, and finally that the transfusion service actively monitors ‘new’ or emerging infectious threats so that action can be taken if the safety of the blood supply is likely to be compromised, as well as maintaining hemovigilance of adverse events in recipients of transfusions.


  • Open Access

    Malaria and blood transfusion

    by A. D. Kitchen, P. L. Chiodini

    The transmission of malaria by blood transfusion was one of the first recorded incidents of transfusion‐transmitted infection. Although a number of different infections have been reported to be transmitted by transfusion since then, on a global scale malaria remains one of the most common transfusion‐transmitted infections. Transfusion‐transmitted malaria can have serious consequences, as infection withPlasmodium falciparummay prove rapidly fatal. Ensuring that, in non‐endemic countries, the blood supply is free from malaria is problematical, especially as travel to malarious areas is increasing and there is some spread of the disease into new areas, as well as a resurgence of malaria in areas where previously it had been eradicated. In non‐endemic countries, donor deferral can be effective, but clear guidelines are needed. In endemic countries the problem is far greater as the majority of donors may be potentially infected with malaria parasites. In both situations, the simple deferral of donors may be wasteful and can eventually erode the donor base. Thus, other strategies are needed to ensure safety with sufficiency. However, the screening of donations for evidence of malaria is not without its problems. Although the examination of blood films is still the basis for diagnosing acute malaria, in most situations it is not sufficiently sensitive for blood bank screening. In non‐endemic countries, donor deferral in combination with screening for specific antimalarial immunoglobulin provides an effective means of minimizing the risk of transmission. In endemic countries, more specific donor questioning, consideration of seasonal variation and geographical distribution may help to identify the population of donors who are most likely to be infected. In addition, the administration of antimalarials to transfusion recipients may help to prevent transmission. Nonetheless, no matter what strategy is adopted, it is likely that cases of transfusion‐transmitted malaria may still occur, so malaria must always be considered in any patient with a febrile illness post‐transfusion.


  • Documented cases of post‐transfusion malaria occurring in England: a review in relation to current and proposed donor‐selection guidelines

    by A. D. Kitchen, J. A. J. Barbara, P. E. Hewitt

    Background and Objectives  Although uncommon, five cases of transfusion‐transmitted malaria have been documented in England over the last 20 years. With the reappearance onto the market of high‐quality malaria antibody assays, and by utilizing the results of analysis of these five cases, it has been possible to review the donor malaria‐deferral guidelines.Materials and Methods  Details of the five cases of post‐transfusion malaria were reviewed against the proposed new donor‐deferral guidelines for malaria.Results  Three of the five cases of post‐transfusion malaria were directly attributable to the deferral guidelines, allowing infectious donors to be bled.Conclusions  The proposed new guidelines will prevent further cases of transmission from semi‐immune individuals.


  • Transfusion‐transmitted malaria: current donor selection guidelines are not sufficient

    by A. Kitchen, A. Mijovic, P. Hewitt

    A case of transfusion‐transmitted malaria was identified in a 50‐year‐old male patient with sickle cell disease. The donor was Ghanaian, but had migrated to the UK some years previously and had not left the UK for 8 years. The donor met all of the extant donor selection guidelines [1] and a donation was consequently collected. However, on subsequent investigation of the case, the donor was found to be parasitaemic and have high titre malarial antibodies. As a result of this case, changes to the United Kingdom donor selection guidelines have been proposed. These changes will prevent any such further transmissions.


  • Evaluation of a malarial antibody assay for use in the screening of blood and tissue products for clinical use

    by A. D. Kitchen, P. H. J Lowe, K. Lalloo, P. L. Chiodini

    A new recombinant Plasmodium antigen enzyme immunoassay (EIA) for the detection of malarial antibodies was evaluated for the screening of 'malaria-risk' blood and tissue donations. A total of 13,269 donor and patient samples were tested by both the EIA and the standard diagnostic antibody immunofluorescence test (IFAT). A total of 114/138 (82.6%) samples from patients with P. falciparum and 11/13 (84.6%) samples from patients with P. vivax tested positive. A total of 714/13,053 (5.47%) samples from donors identified as 'malaria risk', owing to residency or travel, were reactive in the EIA. The assay is more sensitive than a previously implemented malarial antibody EIA (73% in acute P. falciparum and 56% in acute P. vivax infections). The sensitivity of this new EIA is comparable to that of the IFAT, and the specificity is sufficient to screen 'malaria-risk' donors.